Pharmacy

Your Article Summary

See Latest Articles

Caspofungin for the treatment of candidaemia in patients with haematological malignancies
Clinical Microbiology and Infection, 06/29/09

Pagano L et al. - In a study to evaluate the efficacy of caspofungin in neutropenic pts with haematological malignancies (HM) and candidaemia, results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.

• This study was prospectively conducted in 11 haematology divisions over a 2-yr period to evaluate the efficacy of caspofungin in 24 neutropenic pts with haematological malignancies (HM) and candidaemia.

• Pts had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 109/L) for a median of 12 days (2–41) before candidaemia.
• Pts received caspofungin for a median duration of 12 days, obtaining a favourable overall response of 58%.
• At 30 days, 11 pts had died (46%); candidaemia was responsible for mortality in 6 pts (25%).

Today in Antimicrobials...keeping you current

Receive free subspecialty "5-minute updates" via email

Chronic Obstructive Pulmonary Disease: Role of Bacteria and Updated Guide to Antibacterial Selection in the Older Patient
Drugs & Aging, 11/25/09

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
Pediatric Cardiology, 11/18/09

Clinical Importance of Purulence in Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections
Journal of the American Board of Family Medicine, 11/09/09

See All of Antimicrobials